Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.

Franz Maximilian Rasche1, Christoph Hubert Klotz, David Czock

  • 1Division of Nephrology, Department of Internal Medicine II, University of Ulm, Ulm, Germany. maximilian.rasche@medizin.uni-ulm.de

Nephron. Clinical Practice
|May 22, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Medication during heatwaves].

MMW Fortschritte der Medizin·2026
Same author

A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2026
Same author

Sex and Gender Differences in Chronic Kidney Disease-Explained by the Brenner-Luyckx Concept of Hyperfiltration.

Journal of clinical medicine·2026
Same author

Companionship at hospital discharge and its association with subsequent delirium onset in older adults - the TRADE observational study.

BMC geriatrics·2026
Same author

Multidisciplinary guidelines on renal replacement therapy in intensive care medicine.

Critical care (London, England)·2026
Same author

[Polypharmacy and nephrotoxicity].

Innere Medizin (Heidelberg, Germany)·2026

Intravenous cyclophosphamide pulse (CyP) therapy shows promise for advanced IgA nephropathy (IgAN). This treatment significantly reduced the rate of kidney function loss in patients with progressive IgAN.

Area of Science:

  • Nephrology
  • Immunosuppressive therapy

Background:

  • Advanced progressive IgA nephropathy (IgAN) lacks established treatments.
  • Current therapeutic options for IgAN are limited, especially in advanced stages.

Purpose of the Study:

  • To evaluate the efficacy of intravenous cyclophosphamide pulse (CyP) therapy in preserving renal function in patients with advanced progressive IgAN.
  • To assess the impact of CyP on disease progression, proteinuria, and renal function in this patient cohort.

Main Methods:

  • A prospective, uncontrolled trial involving 21 patients with biopsy-proven IgAN and impaired renal function.
  • Patients received intravenous CyP (750 mg/m(2)) every 4 weeks for 6 months, combined with low-dose oral prednisolone.

Main Results:

Related Experiment Videos

  • The annual rate of renal function loss decreased significantly from 16% before therapy to 4% after therapy (p < 0.001).
  • Proteinuria showed a significant reduction during CyP treatment.
  • A lower nadir in white blood cell and platelet counts correlated with improved renal outcomes (p = 0.025).

Conclusions:

  • Intravenous cyclophosphamide pulse therapy, alongside low-dose prednisolone, is effective in preserving renal function for a subset of patients with advanced progressive IgAN.
  • Further research is warranted to identify predictors of response and optimize treatment strategies for IgAN.